111 related articles for article (PubMed ID: 2963205)
1. Climacteric symptoms after oral and percutaneous hormone replacement therapy.
Jensen PB; Jensen J; Riis BJ; Rødbro P; Strøm V; Christiansen C
Maturitas; 1987 Nov; 9(3):207-15. PubMed ID: 2963205
[TBL] [Abstract][Full Text] [Related]
2. Progestogens: therapeutic and adverse effects in early post-menopausal women.
Marslew U; Riis B; Christiansen C
Maturitas; 1991 Mar; 13(1):7-16. PubMed ID: 1830636
[TBL] [Abstract][Full Text] [Related]
3. New natural oestradiol/cyproterone acetate oral contraceptive for pre-menopausal women.
Hirvonen E; Stenman UH; Mälkönen M; Rasi V; Vartiainen E; Ylöstalo P
Maturitas; 1988 Oct; 10(3):201-13. PubMed ID: 2972897
[TBL] [Abstract][Full Text] [Related]
4. Comparison of serum oestrogen concentrations in post-menopausal women taking oestrone sulphate and oestradiol.
Anderson AB; Sklovsky E; Sayers L; Steele PA; Turnbull AC
Br Med J; 1978 Jan; 1(6106):140-2. PubMed ID: 620226
[TBL] [Abstract][Full Text] [Related]
5. Long-term and withdrawal effects of two different oestrogen-progestogen combinations on lipid and lipoprotein profiles in post-menopausal women.
Jensen J; Riis BJ; Strøm V; Christiansen C
Maturitas; 1989 Jun; 11(2):117-28. PubMed ID: 2547137
[TBL] [Abstract][Full Text] [Related]
6. A comparison of liver protein induction in postmenopausal women during oral and percutaneous oestrogen replacement therapy.
Holst J; Cajander S; Carlström K; Damber MG; von Schoultz B
Br J Obstet Gynaecol; 1983 Apr; 90(4):355-60. PubMed ID: 6682335
[TBL] [Abstract][Full Text] [Related]
7. The long-term effect of oral and percutaneous estradiol on plasma renin substrate and blood pressure.
Hassager C; Riis BJ; Strøm V; Guyene TT; Christiansen C
Circulation; 1987 Oct; 76(4):753-8. PubMed ID: 3308164
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms.
Speroff L; Whitcomb RW; Kempfert NJ; Boyd RA; Paulissen JB; Rowan JP
Obstet Gynecol; 1996 Oct; 88(4 Pt 1):587-92. PubMed ID: 8841224
[TBL] [Abstract][Full Text] [Related]
9. Secretory endometrial protein PP14 in serum from post-menopausal women receiving continuous combined oestradiol-cyproterone acetate: correlation with serum hormone concentrations and bleeding patterns.
Byrjalsen I; Thormann L; Riis BJ; Christiansen C
Maturitas; 1992 Aug; 15(1):39-46. PubMed ID: 1388220
[TBL] [Abstract][Full Text] [Related]
10. Absorption of an oestrogen-progestogen preparation.
Staland B
Maturitas; 1983 Aug; 5(2):85-8. PubMed ID: 6633271
[TBL] [Abstract][Full Text] [Related]
11. Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding.
Marslew U; Overgaard K; Riis BJ; Christiansen C
Obstet Gynecol; 1992 Feb; 79(2):202-10. PubMed ID: 1309944
[TBL] [Abstract][Full Text] [Related]
12. Percutaneous oestrogen therapy opposed by lynestrenol or natural progesterone--effects on circulating oestrogens, FSH, sex hormone binding globulin and pregnancy zone protein.
Holst J; Cajander S; Carlström K; Damber MG; von Schoultz B
Maturitas; 1983 Jun; 5(1):1-8. PubMed ID: 6410156
[TBL] [Abstract][Full Text] [Related]
13. [Vaginal estradiol and progesterone in climacteric therapy].
Pedersen OD; Jensen HK
Ugeskr Laeger; 1989 Aug; 151(32):2016-9. PubMed ID: 2672496
[TBL] [Abstract][Full Text] [Related]
14. The effect of a novel vaginal ring delivering oestradiol acetate on climacteric symptoms in postmenopausal women.
Buckler H; Al-Azzawi F;
BJOG; 2003 Aug; 110(8):753-9. PubMed ID: 12892687
[TBL] [Abstract][Full Text] [Related]
15. An oestrone-releasing vaginal ring in the treatment of climacteric women.
Sipinen S; Lähteenmäki P; Luukkainen T
Maturitas; 1980 Dec; 2(4):291-9. PubMed ID: 7231201
[TBL] [Abstract][Full Text] [Related]
16. Plasma oestrone, oestradiol and gonadotrophin concentrations in postmenopausal patients treated with oestradiol or with a combination of oestradiol and oestriol.
Sipinen S
Ann Clin Res; 1979 Oct; 11(5):172-8. PubMed ID: 121048
[TBL] [Abstract][Full Text] [Related]
17. Effects of smoking on serum lipoproteins and bone mineral content during postmenopausal hormone replacement therapy.
Jensen J; Christiansen C
Am J Obstet Gynecol; 1988 Oct; 159(4):820-5. PubMed ID: 2972209
[TBL] [Abstract][Full Text] [Related]
18. Hormone replacement therapy: lipid responses to continuous combined oestrogen and progestogen versus oestrogen monotherapy.
Metka M; Hanes V; Heytmanek G
Maturitas; 1992 Aug; 15(1):53-9. PubMed ID: 1326708
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerance of Menorest compared to Premarin in the treatment of postmenopausal women. A randomised, multicentre, double-blind, double-dummy study.
Studd JW; McCarthy K; Zamblera D; Burger HG; Silberberg S; Wren B; Dain MP; Le Lann L; Vandepol C
Maturitas; 1995 Sep; 22(2):105-14. PubMed ID: 8538478
[TBL] [Abstract][Full Text] [Related]
20. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
